One Wealth Management Investment & Advisory Services LLC Decreases Stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)

One Wealth Management Investment & Advisory Services LLC cut its holdings in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) by 89.3% during the 2nd quarter, Holdings Channel.com reports. The firm owned 15,041 shares of the company’s stock after selling 125,361 shares during the quarter. One Wealth Management Investment & Advisory Services LLC’s holdings in NRx Pharmaceuticals were worth $37,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, AdvisorShares Investments LLC bought a new stake in shares of NRx Pharmaceuticals in the fourth quarter valued at approximately $296,000. 4.27% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on NRXP shares. HC Wainwright lifted their price objective on shares of NRx Pharmaceuticals from $2.00 to $19.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Ascendiant Capital Markets reduced their price target on NRx Pharmaceuticals from $50.00 to $43.00 and set a “buy” rating for the company in a research report on Friday, June 7th.

NRx Pharmaceuticals Price Performance

Shares of NRXP traded down $0.02 during midday trading on Friday, hitting $1.63. 32,128 shares of the company traded hands, compared to its average volume of 218,502. The stock has a 50-day moving average of $2.13 and a 200-day moving average of $12.58. NRx Pharmaceuticals, Inc. has a one year low of $1.59 and a one year high of $7.33. The firm has a market cap of $17.44 million, a P/E ratio of -0.52 and a beta of 1.25.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its earnings results on Wednesday, August 14th. The company reported ($0.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.06. Sell-side analysts forecast that NRx Pharmaceuticals, Inc. will post -3.25 EPS for the current fiscal year.

NRx Pharmaceuticals Profile

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.